The global 3d printed drugs market size is worth around USD 519.9 million in 2024 and is predicted to hit around USD 1,265.1 million by 2034, growing at a CAGR of 9.3% from 2024 to 2034.
The key factor driving growth of the 3D-printed drugs market is the boosted pharmaceutical infrastructure. Increased demands for personalized medicines are driving innovation and developments of novel drugs, leading to a search for the adoption of 3D-printed drugs. Increased prevalence of chronic diseases worldwide is searching for effective and innovative treatments. Additionally, advanced 3D printing technologies are offering extensive speed, resolution, and compatibility to the researchers. Boosted spending on healthcare and government support is enhancing the adoption of cutting-edge technologies like 3D printer drugs. The easy handling, installation, and ability to reduce waste and improve speed are the factors attracting the research and development sector for the adoption of the 3D printers. Technology advancements like inkjet printers are emerging in the market.
North America dominated the 3D-printed drugs market with the presence of competitive landscapes and a large research & development sector in the region. Increased prevalence of chronic disease in the United States is driving government focus toward investments and support for the cutting-edge research in the country, leading to fueling market growth.
Published by Ajit Bansod
